November 24, 2014 7:27 AM ET

Pharmaceuticals

Company Overview of Novartis Pharma AG

Company Overview

Novartis Pharma AG provides treatments for Alzheimer’s disease, Parkinson’s disease, Attention-Deficit/Hyperactivity Disorder, epilepsy, schizophrenia, and migraine. It is also developing a treatment for type 2 diabetes; drugs therapies that improve insulin action to increase glucose disposal in the muscle, to limit its production in the liver, and to improve the kinetics of insulin secretion; and oral and physiological approach to enhancing glucagon like peptide-1 activity, which acts to stimulate insulin secretion and inhibit glucagon production. The company is based in Basel, Switzerland. Novartis Pharma AG operates as a subsidiary of Novartis AG.

Lichtstrasse 35

Basel,  4002

Switzerland

Phone:

41 61 324 11 11

Fax:

41 61 324 80 01

Key Executives for Novartis Pharma AG

President of HBA Europe and Head of New Marketing Initiatives
Global Head of Respiratory and Dermatology
Compensation as of Fiscal Year 2014.

Novartis Pharma AG Key Developments

Genmab Reaches Deal to Transfer Ofatumumab Collaboration with GSK to Novartis

Genmab A/S has entered into an agreement with GlaxoSmithKline and Novartis Pharma AG to transfer the ofatumumab collaboration with GSK to Novartis. The transfer of the collaboration follows an April 2014 announcement in which Novartis, as part of a definitive agreement reached with GSK, agreed to acquire GSK's oncology products including ofatumumab. The transfer of the collaboration will only become effective upon closing of the GSK/Novartis Transaction, which is currently expected in the first half of 2015. Upon transfer, Novartis would develop and commercialize ofatumumab in oncology indications and GSK would continue to develop and commercialize ofatumumab for autoimmune indications. The parties have also agreed that Genmab would not be required to pay existing funding liabilities (approximately GBP 19 million or DKK 180 million)or to fund research and development costs for ofatumumab beyond December 31, 2014. In aggregate, this could reduce Genmab's funding commitment by up to GBP 60 million or DKK 570 million.

Novartis Pharma AG Presents at BIO-Europe 2014, Nov-03-2014 03:15 PM

Novartis Pharma AG Presents at BIO-Europe 2014, Nov-03-2014 03:15 PM. Venue: Portalhaus Messe Frankfurt, Strasse der Nationen, 60327 Frankfurt, Germany. Speakers: Markus Kalousek, Global BD&L, S&E Franchise Head, Integrated Hospital Care.

Novartis Pharma AG Presents at 14th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-30-2014 through Oct-01-2014

Novartis Pharma AG Presents at 14th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-30-2014 through Oct-01-2014. Venue: Congress Center Basel, MCH Messe Schweiz (Basel) AG, CH-4005 Basel, Switzerland. Presentation Date & Speakers: Oct-01-2014, Corinne Savill, Head BD&L. Sep-30-2014, Anthony Rosenberg, Head of BD and Licensing, Guy Greiveldinger, Director BD&L and M&A, Rao Movva, Novartis Distinguished Scientist, Executive Director.

Similar Private Companies By Industry

Company Name Region
Delta Medical Promotions AG Europe
Biotie Therapies AG Europe
Clinuvel AG Europe
Johnson & Johnson AG Europe
Sigma-Tau Pharma AG Europe

Recent Private Companies Transactions

Type
Date
Target
Private Placement
August 18, 2014
Gamida Cell Ltd.
Merger/Acquisition
June 9, 2014
Idenix Pharmaceuticals Inc.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Novartis Pharma AG, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.